BCR

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Retrieved on: 
星期四, 三月 28, 2024
Patient, BCR, Acute leukemia, CML, Therapy, ATP, Pharmaceutical industry

ET to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid leukemia (CML) landscape.

Key Points: 
  • ET to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid leukemia (CML) landscape.
  • ELVN-001 is a highly selective, small molecule kinase inhibitor designed to specifically target the ATP-pocket of the BCR-ABL gene fusion, the oncogenic driver for patients with CML.
  • The discussion will cover ELVN-001’s Phase 1a initial proof of concept data, the evolving treatment paradigm in CML, and how ELVN-001 could fit into the CML landscape.
  • The event will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at https://ir.enliventherapeutics.com/ .

Cellecta, Inc. Launches DriverMap™ Adaptive Immune Receptor (AIR) Human RNA Spike-In Controls to Ensure Consistent Quality and Optimal Performance of TCR and BCR Profiling Assays

Retrieved on: 
星期四, 四月 4, 2024
PCR, QC, Gene, Data analysis, RT, Bias, BCR, Calibration, NGS, Biomarker, Research, RNA, Messenger, Workflow, Immunity, TCR, Collection, AIR, Vaccine

MOUNTAIN VIEW, Calif., April 4, 2024 /PRNewswire/ -- Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) Human RNA Spike-In Premixed Controls, the first commercially available collection of synthetic mRNA constructs that can serve as universal controls for commercial or home-brewed AIR repertoire sequencing (AIR-Seq, TCR-seq and BCR-seq) assays based on multiplex RT-PCR or 5' RACE PCR techniques.

Key Points: 
  • The first-to-market DriverMap™ AIR RNA TCR/BCR spike-in calibration controls measure the accuracy, sensitivity, and linear range of sequencing-based immune repertoire profiling assays.
  • The DriverMap™ AIR RNA Spike-In Controls' key characteristics include:
    These controls consist of 48 B-Cell Receptor (BCR) and 39 T-Cell Receptor (TCR) synthetic mRNA constructs designed to mimic all the different and most abundant TCR and BCR genes.
  • These standards and controls will help attain the goal of more reliable and reproducible AIR sequencing (AIR-Seq) data harmonization, interpretation, and sharing.
  • For more information on the DriveMap AIR RNA Spike-In Controls, including introductory pricing, visit www.cellecta.com/DriverMapAIR or email [email protected] .

Hanwha Vision Delivers AI for Every Surveillance Application at ISC West 2024

Retrieved on: 
星期三, 四月 3, 2024
Algorithm, Logistic, SSD, Data analysis, Pedestrian, BCR, Classification, Reproduction, AI, ISC, FIPS, CCTV, Drive, Vision, TB, Solid, LED, Marketing, Animal, NVR, WAVE, Artificial intelligence, Barcode, Camera

TEANECK, N.J., April 3, 2024 /PRNewswire-PRWeb/ -- Hanwha Vision is highlighting the critical role of Artificial Intelligence (AI) in diverse surveillance and business operations at ISC West 2024, Booth #14025, April 10-12 in Las Vegas. AI will be prominent throughout the Hanwha Vision booth, with many new and existing products now incorporating AI technology to boost their performance to unprecedented levels.

Key Points: 
  • Hanwha Vision will be showcasing new surveillance solutions at ISC West 2024, Booth #14025, April 10-12 in Las Vegas.
  • TEANECK, N.J., April 3, 2024 /PRNewswire-PRWeb/ -- Hanwha Vision is highlighting the critical role of Artificial Intelligence (AI) in diverse surveillance and business operations at ISC West 2024, Booth #14025, April 10-12 in Las Vegas.
  • AI will be prominent throughout the Hanwha Vision booth, with many new and existing products now incorporating AI technology to boost their performance to unprecedented levels.
  • The new AI-powered products from Hanwha Vision to be featured at ISC West include:
    This new camera, available in 8- and 5-megapixel resolution models, combines AI with white LED and infrared lights.

Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting

Retrieved on: 
星期五, 三月 22, 2024
Civil service commission, Metastasis, American Urological Association, Prostate cancer, Astellas Pharma, Patient, BCR, Committee, EMA, Senior, European Medicines Agency, European, MPH, Safety, European Commission, FDA, CHMP, Food, Pharmaceutical industry

TOKYO, March 22, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of XTANDI™ (enzalutamide) as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.1

Key Points: 
  • With approximately 9 out of 10 of these men developing metastatic disease, the need for new and effective treatment options is critical.
  • Today's positive opinion from the Committee is an important step forward for providing an additional treatment option for these patients and complements the existing efficacy and safety data supporting the use of XTANDI across the prostate cancer disease continuum.
  • Astellas is also discussing the EMBARK data with other regulatory authorities to support additional license applications for XTANDI in this indication in 2024 and beyond.
  • Astellas has already reflected the impact from this result in its financial forecast for the current fiscal year ending March 31, 2024.

Oka, The Carbon Insurance Company™ (Oka) and Oregon Biochar Solutions Bring First Insured Biochar Credits to Market

Retrieved on: 
星期四, 三月 14, 2024
Carbon, Business, CDR, Partnership, BCR, Business development, Insurance, OBS, VCM, WEF, Renewable energy

PARK CITY, Utah, March 14, 2024 /PRNewswire/ -- Oka, The Carbon Insurance Company™ (Oka) has partnered with Oregon Biochar Solutions (OBS) to bring world-first invalidation-insured biochar credits to the voluntary carbon market (VCM).

Key Points: 
  • PARK CITY, Utah, March 14, 2024 /PRNewswire/ -- Oka, The Carbon Insurance Company™ (Oka) has partnered with Oregon Biochar Solutions (OBS) to bring world-first invalidation-insured biochar credits to the voluntary carbon market (VCM).
  • Facilitated by OBS project proponent GECA Environnement (GECA), the collaboration sets a new record in the VCM and an ambitious new benchmark for high-quality biochar carbon removal (BCR) credits.
  • Demand is surging for carbon dioxide removal (CDR) projects, with BCR accounting for 94% of all such credit deliveries in 2023.
  • Being the first out of the gate with insurance-wrapped biochar credits sets OBS and the GECA portfolio at the forefront of the market  and sends a critical signal of quality to our customers."

Summary of opinion: Xtandi, 21/03/2024 Positive

Retrieved on: 
星期三, 四月 3, 2024
Civil service commission, Prostate cancer, Disease, BCR, Committee, CRPC, Medication package insert, European Commission, Marketing, CHMP, Birth control

The CHMP adopted a new indication for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer.

Key Points: 
  • The CHMP adopted a new indication for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer.
  • - in combination with androgen deprivation therapy for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) (see section 5.1).
  • - for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).
  • - for the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.

Summary of opinion: Xtandi, 21/03/2024 Positive

Retrieved on: 
星期三, 四月 3, 2024
Civil service commission, Prostate cancer, Disease, BCR, Committee, CRPC, Medication package insert, European Commission, Marketing, CHMP, Birth control

The CHMP adopted a new indication for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer.

Key Points: 
  • The CHMP adopted a new indication for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer.
  • - in combination with androgen deprivation therapy for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) (see section 5.1).
  • - for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).
  • - for the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.

Summary of opinion: Xtandi, 21/03/2024 Positive

Retrieved on: 
星期三, 四月 3, 2024
Civil service commission, Prostate cancer, Disease, BCR, Committee, CRPC, Medication package insert, European Commission, Marketing, CHMP, Birth control

The CHMP adopted a new indication for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer.

Key Points: 
  • The CHMP adopted a new indication for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer.
  • - in combination with androgen deprivation therapy for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) (see section 5.1).
  • - for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).
  • - for the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.

Castellum, Inc. Announces Closing of $4 Million Revolver with Live Oak Bank

Retrieved on: 
星期五, 二月 23, 2024
CTM, Security (finance), Live Oak Bank, Federation, Trust, BCR

BETHESDA, Md., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE-American: CTM), a cybersecurity and software services company focused on the federal government, announces that it has closed its previously announced $4 million financing with Live Oak Bank .

Key Points: 
  • BETHESDA, Md., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE-American: CTM), a cybersecurity and software services company focused on the federal government, announces that it has closed its previously announced $4 million financing with Live Oak Bank .
  • Castellum, Inc. ("Castellum") now has a $4 million revolving credit facility secured by cash, receivables, and the Company's other assets.
  • As part of the transaction, Castellum rolled over approximately $625,000 drawn down on its existing revolver with Live Oak Bank, paid down $400,000 owed to Robert Eisiminger, and paid down approximately $809,000 owed to the Buckhout Charitable Remainder Trust (the "BCR Trust").
  • "As we continue to amortize our existing term loan with Live Oak Bank, our debt/cash operating profit ratio keeps improving, and we position ourselves for a much brighter future.

Seismic Therapeutic to Present Preclinical Data for Novel Immunoglobulin Sculpting Enzyme at AAN Annual Meeting

Retrieved on: 
星期五, 三月 8, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, AAN, Myasthenia gravis, Immunoglobulin G, Autoimmunity, Outline, Novel, Pharmacology, BCR, American Academy, Vaccine

Seismic Therapeutic, Inc ., the machine learning immunology company, today announced that the company will present preclinical data for its pan-immunoglobulin G (IgG) sculpting enzyme candidate, S-1117, at the American Academy of Neurology (AAN) annual meeting taking place on April 13-18 in Denver.

Key Points: 
  • Seismic Therapeutic, Inc ., the machine learning immunology company, today announced that the company will present preclinical data for its pan-immunoglobulin G (IgG) sculpting enzyme candidate, S-1117, at the American Academy of Neurology (AAN) annual meeting taking place on April 13-18 in Denver.
  • S-1117 is a novel engineered pan-IgG protease for the potential treatment of a range of chronic and acute autoantibody mediated diseases, including the chronic neuromuscular autoimmune disorder, myasthenia gravis.
  • The presentation at the AAN annual meeting will outline key preclinical in vitro and in vivo results supporting the differentiated profile of S-1117 compared to therapeutic benchmarks in chronic autoantibody mediated diseases.
  • Title: Preclinical Pharmacology of S-1117, a Novel Engineered Fc-fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases